BioCryst Pharmaceuticals (BCRX)
(Real Time Quote from BATS)
$4.17 USD
+0.01 (0.24%)
Updated Apr 29, 2024 11:52 AM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCRX 4.17 +0.01(0.24%)
Will BCRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Other News for BCRX
First Week of BCRX December 20th Options Trading
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
BioCryst to Report First Quarter 2024 Financial Results on May 6
FYBR, BCRX and SABR are among after hour movers
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency